Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of Tetanus, Diphtheria and Mono Component Acellular Pertussis (TdaP) Vaccine in Comparison to Tetanus and Diphtheria (Td) Vaccine When Given as Booster Vaccinations to Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy female or male adult of ≥ 18 years of age~2. Completed primary vaccination with diphtheria (D), Tetanus (T) and whole cell pertussis (wP) vaccines in Denmark~3. Signed informed consent~4. Prepared to grant authorised persons access to medical records~5. Likely to comply with instructions~Exclusion Criteria:~1. Congenital or acquired immunodeficiency or progressive neurologic disease~2. Uncontrolled epilepsy or progressive encephalopathy~3. Previous experience of serious adverse reaction(s) after vaccinations with diphtheria-, tetanus- acellular or whole cell pertussis- vaccines~4. Vaccinated with any diphtheria, tetanus or pertussis toxoid containing vaccine within 5 years before inclusion~5. Vaccinated with any tetanus toxoid, diphtheria toxoid or diphtheria CRM197 protein conjugated vaccine within 5 years before inclusion~6. Known tetanus-, diphtheria- or pertussis disease/infection within 5 years before inclusion~7. Known hypersensitivity or history of allergic reactions to any of the active or inactive constituents of the TdaP or Td vaccines~8. Vaccinated with a live or inactivated vaccine within 1 month before inclusion~9. Administration of immune modulating drugs (such as immunoglobulin, systemic corticosteroids, blood products, azathioprine, cyclosporine, infliximab) within 3 months before inclusion~10. Administration of any investigational drug product or vaccine within 1 month before inclusion~11. Females if pregnant or breastfeeding or not willing to use contraception during the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- TdaP vaccine (Type: EXPERIMENTAL): None
- Td vaccine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).